We are a UK-based injectable GnRH company that is looking to go to Phase 3 trials in prostate cancer and benign prostatic hyperplasia in the next 18 months. We have dosed over 850 times with no drug-related SAEs and we have excellent site reaction from our injections in contrast to our only injectable competitor, Degerelix. Recent pilot trial data has highlighted the CV risk associated with agonists is potentially four times higher than with antagonists when treating high risk CV patients.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):